Medical Marijuana, Inc. is excited to announce that the Brazilian government has authorized the importation of Real Scientific Hemp Oil™ (RSHO™) to treat a patient diagnosed with Autism Spectrum Disorder – or ASD. This approval is the first time ANVISA, Brazil’s health authority, has granted a special import authorization for RSHO™ as part of treatment for an autism patient in the country.
“We commend the Brazilian government for its compassionate approach to cannabis and for recognizing the need for alternative treatments to treat medical conditions for which there are currently no cure,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc.
Patients in Brazil with a doctor’s prescription can petition ANVISA for permission to import RSHO™ for any condition. Medical Marijuana, Inc.’s local distribution branch, HempMeds® Brasil, revealed earlier this year that ANVISA also approved import applications for RSHO™ to assist patients in the country suffering the effects of Multiple Sclerosis and Alzheimer’s disease.
According to the National Institute of Mental Health, Autism Spectrum Disorder is the name for a number of neurodevelopmental disorders that include a “spectrum” of common symptoms. ASD develops in infancy or childhood and is characterized by social interaction difficulties, verbal and physical communication impairments, and restricted and repetitive patterns of behavior. According to the Centers for Disease Control and Prevention, 1 in 68 children in the U.S. currently display signs of ASD. Doctors diagnose ASD by observing a child’s behavior and development, noting possible symptoms of autism.
In Brazil, recent statistics reveal that 1.5 million total children have autism. The country’s rate of 27.2 cases per 10,000 children studied makes Brazil 8th in the world for ASD incidence rate, making an effective treatment option a critical need.
Children diagnosed with ASD often face a greater degree of cognitive impairment and have difficulty with interpersonal interaction, meaning that they may require special care, like adaptations in formal education. Autism has only been recognized as a disability by the Brazilian government since 2012, when extensive lobbying by parent advocates led to a change in federal law in Brazil.
Dr. Titus went on to say, “We hope that this most recent decision by ANVISA will bring light to additional families in Brazil who have children with autism that could benefit from access to our hemp oil. We’re optimistic about several new studies being conducted on the potential benefits of cannabis on individuals with autism.”
Among the ongoing research into autism is an exciting new study out of Mexico. Neurosurgeon Dr. Saul Garza has revealed that he is currently enrolling patients for a study on the effects of CBD oil on autism spectrum disorder in the hope of offering additional treatment options for patients living with autism.
Patients in Brazil who have received a prescription from their doctor for CBD oil for their personal condition can apply to ANVISA for authorization to import RSHO™. If you are in Brazil and looking to purchase RSHO™ CBD oil, get started by visiting the HempMeds® Brasil Patient’s Page or contact our team at (21) 4042-2095 with any questions you might have.
Learn more about HempMeds® Brasil and the rest of the Medical Marijuana, Inc. portfolio of companies by following our news feed.